IUGNF - Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial

(NewsDirect)

Imugene Ltd(ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company ispreparing 10 clinical trial sites in Australia and the UK for a newPD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial set to beginin 2024. The company intends to enrol 44 patients across the sixAustralian and four UK sites, to participate in the study for about 18months. The primary objective of the trial is to determine majorpathological response rates, a measurement of tumour size, aftertreating with PD1-Vaxx but before surgery to remove any residualtumour – also known as neoadjuvant in operable CRC cancerpatients.

“Weare excited to commence this important Phase 2 trial with PD1-Vaxxafter being approached by the leading colorectal cancer oncologistsfrom both Australia and the UK," Chong said. "The study costsare partially funded being Investigator Sponsored studies, and fallwithin current cash flow forecasts.”

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.